Recent advances in management of small-cell lung cancer.

摘要: Small-cell lung cancer (SCLC) is a smoking-related disease with poor prognosis. While SCLC usually initially sensitive to chemotherapy and radiotherapy, responses are rarely long lasting. Frustratingly, most patients ultimately relapse, often increasingly treatment resistant disease. Many strategies have been developed in an attempt improve outcomes, which plateaued since the introduction of combination 1980s. These include trials maintenance therapy, dose intensification, latter by means increasing density, growth factor support high autologous stem cell rescue. None shown patient survival. On other hand, integration concurrent thoracic radiation prophylactic cranial irradiation has improved survival outcomes limited In extensive disease, irinotecan combined cisplatin promise improving over conventional platinum/etoposide schedules confirmatory study awaited. The future may however lie molecularly targeted therapies, such as antiangiogenesis agents signal transduction inhibitors, being studied at present.